/
Other
Dexamethasone
32
Pipeline Programs↗
46
Active Trials↗
22
Companies Involved↗
Dexamethasone is a moderately active landscape with 32 programs across 22 companies. The most active players are GSK, Bayer. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 211
Phase 310
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
27 of 32 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.
Analysis
Trial Status
305
clinical trials
Completed153 · 50%
Unknown status75 · 25%
Terminated22 · 7%
Recruiting20 · 7%
Active, not recruiting12 · 4%
Not yet recruiting11 · 4%
Other12 · 4%
Clinical Trials
Trial Activity
305 trials
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Recruiting·—·Phase 2·NCT07334379·60 enrolled
Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants
Recruiting·—·Phase 1·NCT05387941·15 enrolled
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Recruiting·—·Phase 1·NCT06863259·28 enrolled
The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia
Recruiting·—·Phase 2·NCT05732883·100 enrolled
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07385131·300 enrolled
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Recruiting·—·N/A·NCT06984822·150 enrolled
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Recruiting·—·Phase 2·NCT04176718·43 enrolled
Page 1 of 21
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)